Intrinsic FGFR2 and Ectopic FGFR1 Signaling in the Prostate and Prostate Cancer

Overview

Journal Front Genet

Date 2019 Feb 15

PMID 30761180

Citations 18

Authors

Cong Wang

Ziying Liu

Yuepeng Ke

Fen Wang

Affiliations

Soon will be listed here.

Abstract

Advanced castrate-resistant prostate cancer (CRPC) is a poorly prognostic disease currently lacking effective cure. Understanding the molecular mechanism that underlies the initiation and progression of CRPC will provide new strategies for treating this deadly disease. One candidate target is the fibroblast growth factor (FGF) signaling axis. Loss of the intrinsic FGF7/FGF10-type 2 FGF receptor (FGFR2) pathway and gain of the ectopic type 1 FGF receptor (FGFR1) pathway are associated with the progression to malignancy in prostate cancer (PCa) and many other epithelial originating lesions. Although FGFR1 and FGFR2 share similar amino acid sequences and structural domains, the two transmembrane tyrosine kinases elicit distinctive, even sometime opposite signals in cells. Recent studies have revealed that the ectopic FGFR1 signaling pathway contributes to PCa progression via multiple mechanisms, including promoting tumor angiogenesis, reprogramming cancer cell metabolism, and potentiating inflammation in the tumor microenvironment. Thus, suppression of FGFR1 signaling can be an effective novel strategy to treat CRPC.

Citing Articles

Genetic ancestry concordant RNA splicing in prostate cancer involves oncogenic genes and associates with recurrence.

Al Abo M, Foo W, Howard L, McGue S, Lacroix B, Kephart J NPJ Precis Oncol. 2025; 9(1):30.

PMID: 39880920 PMC: 11779911. DOI: 10.1038/s41698-025-00817-9.

Prostate cancer microenvironment: multidimensional regulation of immune cells, vascular system, stromal cells, and microbiota.

Chen L, Xu Y, Wang Y, Ren Y, Dong X, Wu P Mol Cancer. 2024; 23(1):229.

PMID: 39395984 PMC: 11470719. DOI: 10.1186/s12943-024-02137-1.

Cancer-associated fibroblasts and prostate cancer stem cells: crosstalk mechanisms and implications for disease progression.

Chen H, Fang S, Zhu X, Liu H Front Cell Dev Biol. 2024; 12:1412337.

PMID: 39092186 PMC: 11291335. DOI: 10.3389/fcell.2024.1412337.

Fibroblast growth factor pathway promotes glycolysis by activating LDHA and suppressing LDHB in a STAT1-dependent manner in prostate cancer.

Ye Y, Yang F, Gu Z, Li W, Yuan Y, Liu S J Transl Med. 2024; 22(1):474.

PMID: 38764020 PMC: 11103983. DOI: 10.1186/s12967-024-05193-9.

Taraxasterol suppresses the proliferation and tumor growth of androgen-independent prostate cancer cells through the FGFR2-PI3K/AKT signaling pathway.

Yang J, Xin C, Yin G, Li J Sci Rep. 2023; 13(1):13072.

PMID: 37567936 PMC: 10421874. DOI: 10.1038/s41598-023-40344-w.

References

Lu W, Luo Y, Kan M, McKeehan W . Fibroblast growth factor-10. A second candidate stromal to epithelial cell andromedin in prostate. J Biol Chem. 1999; 274(18):12827-34. DOI: 10.1074/jbc.274.18.12827. View

Donjacour A, Sciavolino P, Kim M, Desai N, Young P, Norton C . Roles for Nkx3.1 in prostate development and cancer. Genes Dev. 1999; 13(8):966-77. PMC: 316645. DOI: 10.1101/gad.13.8.966. View

Giri D, Ropiquet F, Ittmann M . Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res. 1999; 5(5):1063-71. View

Nakano K, Fukabori Y, Itoh N, Lu W, Kan M, McKeehan W . Androgen-stimulated human prostate epithelial growth mediated by stromal-derived fibroblast growth factor-10. Endocr J. 1999; 46(3):405-13. DOI: 10.1507/endocrj.46.405. View

Ricol D, Cappellen D, el Marjou A, Gil-Diez-de-Medina S, Girault J, Yoshida T . Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer. Oncogene. 1999; 18(51):7234-43. DOI: 10.1038/sj.onc.1203186. View

Portela-Gomes G, Lukinius A, Grimelius L . Synaptic vesicle protein 2, A new neuroendocrine cell marker. Am J Pathol. 2000; 157(4):1299-309. PMC: 1850151. DOI: 10.1016/S0002-9440(10)64645-7. View

McDougall K, Kubu C, Verdi J, Meakin S . Developmental expression patterns of the signaling adapters FRS-2 and FRS-3 during early embryogenesis. Mech Dev. 2001; 103(1-2):145-8. DOI: 10.1016/s0925-4773(01)00337-9. View

Chua S, Ma Z, Gong L, Lin S, DeMayo F, Tsai S . Ectopic expression of FGF-3 results in abnormal prostate and Wolffian duct development. Oncogene. 2002; 21(12):1899-908. DOI: 10.1038/sj.onc.1205096. View

Wang F, McKeehan K, Yu C, McKeehan W . Fibroblast growth factor receptor 1 phosphotyrosine 766: molecular target for prevention of progression of prostate tumors to malignancy. Cancer Res. 2002; 62(6):1898-903. View

10.

Denmeade S, Isaacs J . A history of prostate cancer treatment. Nat Rev Cancer. 2002; 2(5):389-96. PMC: 4124639. DOI: 10.1038/nrc801. View

11.

Song Z, Wu X, Powell W, Cardiff R, Cohen M, Tin R . Fibroblast growth factor 8 isoform B overexpression in prostate epithelium: a new mouse model for prostatic intraepithelial neoplasia. Cancer Res. 2002; 62(17):5096-105. View

12.

Foster B, Evangelou A, Gingrich J, Kaplan P, DeMayo F, Greenberg N . Enforced expression of FGF-7 promotes epithelial hyperplasia whereas a dominant negative FGFR2iiib promotes the emergence of neuroendocrine phenotype in prostate glands of transgenic mice. Differentiation. 2002; 70(9-10):624-32. DOI: 10.1046/j.1432-0436.2002.700915.x. View

13.

Donjacour A, Thomson A, Cunha G . FGF-10 plays an essential role in the growth of the fetal prostate. Dev Biol. 2003; 261(1):39-54. DOI: 10.1016/s0012-1606(03)00250-1. View

14.

Polnaszek N, Kwabi-Addo B, Peterson L, Ozen M, Greenberg N, Ortega S . Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res. 2003; 63(18):5754-60. View

15.

Wang F, McKeehan K, Yu C, Ittmann M, McKeehan W . Chronic activity of ectopic type 1 fibroblast growth factor receptor tyrosine kinase in prostate epithelium results in hyperplasia accompanied by intraepithelial neoplasia. Prostate. 2003; 58(1):1-12. DOI: 10.1002/pros.10311. View

16.

Freeman K, Welm B, Gangula R, Rosen J, Ittmann M, Greenberg N . Inducible prostate intraepithelial neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice. Cancer Res. 2003; 63(23):8256-63. View

17.

Jin C, McKeehan K, Guo W, Jauma S, Ittmann M, Foster B . Cooperation between ectopic FGFR1 and depression of FGFR2 in induction of prostatic intraepithelial neoplasia in the mouse prostate. Cancer Res. 2003; 63(24):8784-90. View

18.

Yan G, Fukabori Y, Nikolaropoulos S, Wang F, McKeehan W . Heparin-binding keratinocyte growth factor is a candidate stromal-to-epithelial-cell andromedin. Mol Endocrinol. 1992; 6(12):2123-8. DOI: 10.1210/mend.6.12.1491693. View

19.

Konno-Takahashi N, Takeuchi T, Nishimatsu H, Kamijo T, Tomita K, Schalken J . Engineered FGF-2 expression induces glandular epithelial hyperplasia in the murine prostatic dorsal lobe. Eur Urol. 2004; 46(1):126-32. DOI: 10.1016/j.eururo.2004.02.004. View

20.

Zhong C, Saribekyan G, Liao C, Cohen M, Roy-Burman P . Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis. Cancer Res. 2006; 66(4):2188-94. DOI: 10.1158/0008-5472.CAN-05-3440. View